Showing results (231-240 of 289) with videos related to
Sort By:
Pageof 29
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2015
Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysisI Fleury, S Chevret, M Pfreundschuh, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1994
First isolated locoregional recurrence following mastectomy for breast cancer: results of a phase III multicenter study comparing systemic treatment with observation after excision and radiation. Swiss Group for Clinical Cancer ResearchM Borner, M Bacchi, A Goldhirsch, et al.British Journal of Cancer|November 1, 1996
Initial prognostic factors in small-cell lung cancer patients predicting quality of life during chemotherapy. Swiss Group for Clinical Cancer Research (SAKK)J Bernhard, C Hürny, M Bacchi, et al.Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 1, 1996
The last 3 months of life of cancer patients: medical aspects and role of home-care services in southern SwitzerlandC Sessa, E Roggero, S Pampallona, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2002
Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study GroupE Zucca, A Conconi, T I Mughal, et al.Hematological Oncology|March 11, 2009
A multicentre phase II trial of gemcitabine for the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma: SAKK 36/03F Hitz, G Martinelli, E Zucca, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 11, 2016
Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomasE Gaudio, C Tarantelli, I Kwee, et al.British Journal of Haematology|June 17, 2026
Metabolic heterogeneity-based radiomic model predicts treatment outcomes of primary mediastinal B-cell lymphoma patients in the IELSG37 studyL Ceriani, L Milan, L Cascione, et al.European Journal of Cancer (Oxford, England : 1990)|October 26, 1999
Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment. Swiss Group for Clinical Cancer Research (SAKK)J Bernhard, M Castiglione-Gertsch, S F Schmitz, et al.Cancer Chemotherapy and Pharmacology|January 1, 1982
Pharmacokinetic approach to the selection of dose schedules for medroxyprogesterone acetate in clinical oncologyV Tamassia, A Battaglia, F Ganzina, et al.Pageof 29